Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-192 in Patients With Advanced Solid Malignancies

Trial Profile

A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-192 in Patients With Advanced Solid Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ICP 192 (Primary)
  • Indications Gastric cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors InnoCare Pharma
  • Most Recent Events

    • 07 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 06 Dec 2018 New trial record
    • 18 Jul 2018 According to an InnoCare Pharma media release, the China Food and Drug Administration has approved Clinical trial application for ICP 192 in solid tumours including gastric cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top